Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Jingyuan Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4820-530X; OpenAlex author ID A5107918934. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 6 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 14

  1. Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. First author DOI 10.1016/j.bbadis.2024.167183↗
  2. Single-cell and spatial transcriptomic analyses reveal the cellular origins and drivers of liver metastasis from pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4128922/v1↗
  3. Correction for: Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pan… Co-author DOI 10.18632/aging.205456↗
  4. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
  5. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Co-author DOI 10.1016/j.bbadis.2021.166213↗
  6. Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. Co-author DOI 10.1016/j.omto.2020.03.006↗
  7. The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. Co-author DOI 10.1016/j.omto.2020.04.011↗
  8. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocar… Co-author DOI 10.18632/aging.102931↗
  9. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Co-author PMID 32064158↗
  10. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression. Co-author PMID 32195024↗
  11. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Co-author PMID 33042621↗
  12. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2019.01.011↗
  13. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. First author DOI 10.1186/s13046-019-1044-z↗
  14. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-018-0888-y↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 12 shared papers, 2018–2024 · strength 1.57
  2. Xin Jin · 11 shared papers, 2018–2023 · strength 1.39
  3. Dianyun Ren · 7 shared papers, 2020–2024 · strength 1.03
  4. Zibo Meng · 7 shared papers, 2019–2023 · strength 0.90
  5. Yan Sun · 4 shared papers, 2020–2024 · strength 0.57
  6. Yingke Zhou · 3 shared papers, 2021–2024 · strength 0.45
  7. Gengdu Qin · 3 shared papers, 2020–2024 · strength 0.43
  8. Ping Fan · 4 shared papers, 2018–2020 · strength 0.42
  9. Chong Yang · 3 shared papers, 2019–2021 · strength 0.35
  10. Taoyu Chen · 2 shared papers, 2022–2024 · strength 0.35
  11. Kun Zhang · 2 shared papers, 2020–2023 · strength 0.34
  12. Shikai Zhu · 2 shared papers, 2020–2022 · strength 0.26
  13. Zhiqiang Liu · 2 shared papers, 2019–2020 · strength 0.22
  14. Shihong Wu · 2 shared papers, 2019–2020 · strength 0.22
  15. Yao Guo · 1 shared paper, 2024 · strength 0.21
  16. Jing Cui · 1 shared paper, 2024 · strength 0.21
  17. Tao Yin · 1 shared paper, 2024 · strength 0.21
  18. Tao Peng · 1 shared paper, 2024 · strength 0.21
  19. Bo Wang · 2 shared papers, 2018–2019 · strength 0.19
  20. Yuhan Zhao · 1 shared paper, 2024 · strength 0.18
  21. Hongkun Cai · 1 shared paper, 2024 · strength 0.18
  22. Penglin Pan · 1 shared paper, 2022 · strength 0.14
  23. Haixin Yu · 1 shared paper, 2022 · strength 0.14
  24. Xiaogang Li · 1 shared paper, 2020 · strength 0.13
  25. Shanmiao Gou · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.